Atogepant: A New Hope for Resistant Migraine Relief
- MigraineMind
- Nov 30, 2025
- 1 min read
Research Summary
A recent study published in the Journal of Headache and Pain explores the effectiveness of atogepant for patients with migraines who did not respond to anti-CGRP monoclonal antibodies. Conducted across multiple centers, this real-world study assessed the drug's safety, persistence, and predictors of response. The researchers found that atogepant effectively reduced migraine frequency in these patients. The study highlights that atogepant was generally well-tolerated, with a safety profile consistent with previous findings. This research provides new insights into treatment options for migraine sufferers who have exhausted other therapies, potentially offering relief for this challenging condition.
Study Details
👥 Research Team: Muñoz-Vendrell A et al.
📚 Published In: J Headache Pain
📅 Publication Date: 2025 Nov 28
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.